Scarica l'app Stockscreener
207.77
1.59%
3.26
Pre-mercato:
207.80
0.03
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$204.51
Aprire:
$206.22
Volume 24 ore:
1.05M
Relative Volume:
0.45
Capitalizzazione di mercato:
$44.31B
Reddito:
$447.02M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-33.61
EPS:
-6.1812
Flusso di cassa netto:
$-906.14M
1 W Prestazione:
+4.53%
1M Prestazione:
+25.70%
6M Prestazione:
+213.10%
1 anno Prestazione:
+173.81%
Intervallo 1D:
$202.88
$208.05
Intervallo di 1 settimana:
$199.52
$209.77
Portata 52W:
$60.40
$209.77
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insmed Insiders Sell US$54m Of Stock, Possibly Signalling Caution - Yahoo Finance
Why Insmed Incorporated stock appeals to analystsJuly 2025 Update & Entry Point Confirmation Signals - BỘ NỘI VỤ
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool
Why Insmed Incorporated stock remains resilient2025 Major Catalysts & Smart Swing Trading Techniques - moha.gov.vn
Targets Report: How Insmed Incorporated (IM8N) stock correlates with oil markets2025 Biggest Moves & Technical Entry and Exit Tips - BỘ NỘI VỤ
Does Insmed Incorporated stock trade at a discount to peers2025 Short Interest & Low Drawdown Trading Strategies - BỘ NỘI VỤ
Insider Sell: Elizabeth Anderson Sells 5,000 Shares of Insmed In - GuruFocus
Is EU Approval of First NCFB Therapy Reframing Insmed’s (INSM) Investment Outlook? - Yahoo Finance
Insmed (INSM) Rose Following Drug Approval - Finviz
What Catalysts Are Shaping the New Narrative for Insmed? - Yahoo Finance
Insmed stock hits 52-week high at 208.14 USD By Investing.com - Investing.com Canada
Insmed stock hits 52-week high at 208.14 USD - Investing.com India
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri - MSN
Trend analysis for Insmed Incorporated this week2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
INSM: TD Cowen Raises Price Target, Maintains Buy Rating | INSM Stock News - GuruFocus
How Insmed Incorporated (IM8N) stock performs in easing cyclesRate Hike & Daily Stock Trend Reports - newser.com
Will Insmed Incorporated (IM8N) stock recover faster than industryFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Insmed wins first EU approval for non-cystic fibrosis bronchiectasis treatment - MarketScreener
Why Insmed Incorporated (IM8N) stock is listed among top recommendationsPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Will Insmed Incorporated stock benefit from automationIndex Update & Accurate Entry/Exit Alerts - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Insider Sell: Leo Lee Sells 75,000 Shares of Insmed Inc (INSM) - GuruFocus
Building trade automation scripts for Insmed IncorporatedCPI Data & Proven Capital Preservation Methods - newser.com
Insmed director Anderson sells $1.96 million in stock By Investing.com - Investing.com South Africa
Insmed director Anderson sells $1.96 million in stock - Investing.com
Insmed Says European Commission Approves Brinsupri for Treatment of Non-Cystic Fibrosis Bronchiectasis - MarketScreener
Peering Into Insmed Inc's Recent Short Interest - Benzinga
Insmed (INSM) Gains EU Approval for First NCFB Treatment - GuruFocus
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - PR Newswire
Insmed (Nasdaq: INSM) BRINSUPRI Wins EU OK After 19.4% NCFB Exacerbation Reduction - Stock Titan
European Commission Approves Insmed's Chronic Lung Disease Treatment - MarketScreener
Insmed at Jefferies London: Transforming into a Multi-Franchise Entity By Investing.com - Investing.com Nigeria
Insmed at Jefferies London: Transforming into a Multi-Franchise Entity - Investing.com
INSM: Brensocatib and TPIP advances fuel growth, with major data and market expansions ahead - TradingView
Transcript : Insmed Incorporated Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - MarketScreener
Here’s What Lifted Insmed Incorporated (INSM) in Q3 - Yahoo Finance
Insmed (INSM) Price Target Increased by 15.76% to 206.22 - Nasdaq
How Insmed Incorporated (IM8N) stock compares with tech leadersJuly 2025 Action & Risk Controlled Stock Alerts - newser.com
Insmed (BIT:1INSM) Price Target Increased by 19.33% to 179.30 - Nasdaq
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.01%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):